Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Xenetic Biosciences's share price for the quarter that ended in Mar. 2026 was $2.68. Xenetic Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 2.29 Mil. Therefore, Xenetic Biosciences's market cap for the quarter that ended in Mar. 2026 was $6.14 Mil.
Xenetic Biosciences's quarterly market cap
increased
from Sep. 2025 ($4.84 Mil) to Dec. 2025 ($4.97 Mil) and
increased
from Dec. 2025 ($4.97 Mil) to Mar. 2026 ($6.14 Mil).
Xenetic Biosciences's annual market cap
increased
from Dec. 2023 ($5.32 Mil) to Dec. 2024 ($6.15 Mil) but then
declined
from Dec. 2024 ($6.15 Mil) to Dec. 2025 ($4.97 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Xenetic Biosciences's Enterprise Value for Today is $-1.00 Mil.
Xenetic Biosciences (NAS:XBIO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Xenetic Biosciences Market Cap Related Terms
Xenetic Biosciences Market Cap Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xenetic Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Xenetic Biosciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (XBIO) has a Market Cap of $6.35 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Xenetic Biosciences and its competitors. According to the industry distribution chart, Xenetic Biosciences ranks #1270 out of 1426 companies in the Biotechnology industry, placing it in the top 89.1%.
Is Xenetic Biosciences' Market Cap too high?
Xenetic Biosciences' current Market Cap is $6.35 Mil. The Biotechnology industry median Market Cap is 119.23. Xenetic Biosciences' value of $6.35 Mil is 94.7% below this industry median. Based on the distribution chart, Xenetic Biosciences ranks #1270 out of 1426 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xenetic Biosciences has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Market Cap compare to ACXP and SILO?
According to the Biotechnology industry distribution chart, Xenetic Biosciences ranks #1270 out of 1426 companies for Market Cap. This places Xenetic Biosciences in the lower half of its industry. The industry median Market Cap is 119.23. Xenetic Biosciences' value of $6.35 Mil is 94.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xenetic Biosciences's current Market Cap of $6.35 Mil is 94.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Xenetic Biosciences and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xenetic Biosciences's current Market Cap is $6.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.19, compared to a current price of $2.77 — trading 33.9% below its estimated fair value. The current Market Cap is $6.35 Mil and 94.7% below the Biotechnology industry median of 119.23. Xenetic Biosciences' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Market Cap is $6.35 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (XBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of $2.77 is trading 33.9% below its estimated GF Value™ of $4.19.
GuruFocus considers Xenetic Biosciences to be Possible Value Trap.
Key valuation signals for XBIO:
Market Cap: $6.35 Mil
GF Value™: $4.19 vs. price of $2.77 (33.9% below fair value)
Industry Position: 94.7% below the Biotechnology median (#1270 of 1426)
No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
79GF Score
Get the complete analysis for XBIO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBIO has been successfully added to your 
